US-based chip manufacturer Nvidia will invest $50 million in biotech firm Recursion to expedite the development of artificial intelligence models for drug discovery.
As per Recursion’s announcement, the company has partnered with Nvidia to fast-track the creation of “innovative” foundational models in AI-assisted drug discovery.
Nvidia’s $50 million investment will support Recursion’s use of AI-powered models to discover and design new treatments.
Recursion plans to utilize biological and chemical datasets exceeding 23,000 terabytes to operate artificial intelligence models on Nvidia’s cloud platform, as mentioned in the company’s statement.
Following the announcement of the investment, Recursion’s shares listed on the Nasdaq stock market saw an increase of over 115 percent.
You may also like this content
- Meta Building World’s Fastest AI Supercomputer for Metaverse
- Artificial Intelligence Will Make Decisions Instead Of People
- Bill Gates: Artificial Intelligence Over Web3 and Metaverse
Follow us on TWITTER (X) and be instantly informed about the latest developments…
